Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
HC Wainwright & Co. analyst Joseph Pantginis reiterates Aptose Biosciences (NASDAQ:APTO) with a Buy and maintains $7 pri...
TUS Monotherapy and TUS+Venetoclax (VEN) Doublet Therapy Show Broad Clinical Activity and Strong Safety Data in relapsed or r...
https://www.zacks.com/stock/news/2288032/aptose-biosciences-apto-upgraded-to-buy-what-does-it-mean-for-the-stock
Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology...
Canaccord Genuity analyst John Newman maintains Aptose Biosciences (NASDAQ:APTO) with a Buy and lowers the price target from...
Aptose Biosciences (NASDAQ:APTO) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(...
Piper Sandler analyst Edward Tenthoff maintains Aptose Biosciences (NASDAQ:APTO) with a Overweight and maintains $5 price ta...
HC Wainwright & Co. analyst Joseph Pantginis maintains Aptose Biosciences (NASDAQ:APTO) with a Buy and maintains $23 pri...
Aptose Biosciences (NASDAQ:APTO) reported quarterly losses of $(1.44) per share which beat the analyst consensus estimate of $(...
